0 references
Ipilimumab + nivolumab in combination vs. nivolumab monotherapy as first-line treatment in patients with metastatic melanoma: conclusions from a real-world French national cohort
British Journal of Dermatology2025Vol. 192(6), pp. 971–972
Related Papers
- → Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2019)3,640 cited
- → Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab(2021)13 cited
- → Utility Values Across Lines of Therapy in Immuno-Oncology Treatments: An Example from Advanced Melanoma(2017)
- → Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients(2023)
- → TNFSF9 is associated with favor tumor immune microenvironment in patients with renal cell carcinoma who are treated with the combination therapy of nivolumab and ipilimumab(2024)